{"product_id":"medexus-pestle-analysis","title":"Medexus Pharma PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our targeted PESTLE Analysis of Medexus Pharma—three to five expertly sourced insights into political, economic, social, technological, legal, and environmental forces shaping its trajectory. Ideal for investors and strategists seeking actionable intelligence; purchase the full report for the complete, editable breakdown and immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS–Canada healthcare policy shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus’ US and Canadian footprint means federal\/state and provincial policy shifts directly affect pricing, access and reimbursement; US Medicare negotiation under the Inflation Reduction Act applies to selected drugs from 2026 (biologics 2028) and Medicaid best-price rules can compress margins. Canadian public formulary decisions and pCPA provincial tendering—pCPA reports \u0026gt;CAD 11.5B savings since 2010—shape volumes and net pricing. Close monitoring and proactive payer engagement mitigate policy risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing reform momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical pressure to lower drug costs in North America remains high, driven by policy tools like Medicare negotiation under the U.S. Inflation Reduction Act (price-setting begins 2026) and growing reference-pricing\/ transparency mandates; the U.S. accounts for roughly 45% of global pharma sales (2023). Expansion of reference pricing, inflation penalties and disclosure rules can cap price hikes on established brands, and specialty autoimmune\/hematology drugs face intensified scrutiny. Scenario planning across multiple pricing pathways is essential for Medexus revenue forecasts and valuation stress-testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment and approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFDA and Health Canada policy priorities shape Medexus approval timelines, labeling and post-market commitments—FDA PDUFA targets 10 months (standard) and 6 months (priority), while Health Canada targets ~300 days standard and ~180 days priority. Accelerated pathways for serious conditions (Breakthrough\/priority) can speed niche-indication launches. Evolving biologics guidance raises evidence thresholds, increasing trial complexity and CMC expectations. A coordinated US\/Canada regulatory strategy can cut duplication and trim time-to-market by about 3–6 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy and supply resilience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eUSMCA, in force since July 1, 2020, shapes cross-border movement of medicines and components across Canada, the US and Mexico and intersects a global pharmaceutical market valued around US$1.5 trillion in 2024; trade frameworks thus materially affect Medexus supply routes. Geopolitical frictions can prompt export controls or inspections that slow logistics, while national incentives for reshoring and manufacturing capacity shifts sourcing economics; diversified suppliers and inventory buffers mitigate disruption risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUSMCA in force since 2020\u003c\/li\u003e\n\u003cli\u003eGlobal pharma market ≈ US$1.5T (2024)\u003c\/li\u003e\n\u003cli\u003eExport controls\/inspections heighten logistic risk\u003c\/li\u003e\n\u003cli\u003eReshoring incentives reshape sourcing\u003c\/li\u003e\n\u003cli\u003eDiversification + inventory buffers reduce exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic funding and rare-disease agendas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment focus on rare diseases and pediatric care can unlock grants, expedited reviews and reimbursement pilots, boosting Medexus Pharma’s ability to advance niche therapies; budget constraints, however, risk delayed formulary listings and access timelines. Active engagement with policymakers and advocacy groups aligns portfolio positioning with public-health priorities, while strategic indication selection maximizes policy tailwinds.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePriority reviews and grants improve time-to-market\u003c\/li\u003e\n\u003cli\u003eBudget limits can delay public reimbursement\u003c\/li\u003e\n\u003cli\u003ePolicymaker engagement aligns portfolio with health agendas\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth American footprint makes Medicare, pCPA, regulatory timing and supply risk margin drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedexus’ US\/Canada footprint makes Medicare negotiation (IR Act price-setting 2026; biologics 2028), Medicaid best-price and pCPA (\u0026gt;$11.5B savings since 2010) key margin drivers. US ≈45% of global pharma sales (2023) and global market ≈US$1.5T (2024) amplify pricing risk. FDA PDUFA 10\/6m vs Health Canada ~300\/180d — regulatory alignment can shave ~3–6m. USMCA, export controls and reshoring incentives heighten supply risk; diversification mitigates.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003e2026 (drugs), 2028 (biologics)\u003c\/td\u003e\n\u003ctd\u003ePrice caps, margin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003epCPA savings\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;CAD 11.5B (since 2010)\u003c\/td\u003e\n\u003ctd\u003eNet pricing compression\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS share\u003c\/td\u003e\n\u003ctd\u003e≈45% (2023)\u003c\/td\u003e\n\u003ctd\u003eRevenue sensitivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal market\u003c\/td\u003e\n\u003ctd\u003e≈US$1.5T (2024)\u003c\/td\u003e\n\u003ctd\u003eMacro exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory timelines\u003c\/td\u003e\n\u003ctd\u003ePDUFA 10\/6m; HC ~300\/180d\u003c\/td\u003e\n\u003ctd\u003eTime-to-market impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Medexus Pharma across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed insights tied to industry and regional regulatory dynamics. Designed for executives and investors, it highlights risks, opportunities and forward-looking scenarios ready for inclusion in reports and plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Medexus Pharma that relieves research friction by highlighting regulatory, market, technological and competitive risks for quick inclusion in presentations, team planning and client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic cycles and demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialty pharma demand is relatively resilient but can be hit by recessions and payer austerity; IQVIA reported specialty medicines accounted for 49.6% of global medicine spend in 2023, showing scale but not immunity. Economic slowdowns tighten hospital budgets and raise prior authorization thresholds, reducing uptake in capital-constrained settings. Employer-sponsored coverage—about 49% of the US population in 2023 per KFF—means employer plan shifts alter commercial lives; forecasts must model elasticity by payer segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eForeign exchange USD\/CAD volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedexus reports revenue and costs in both USD and CAD, exposing it to translation and transaction risk as USD\/CAD has swung widely (peaking near 1.46 in Sept 2022 and trading around 1.35–1.37 through 2024). Such FX moves can distort reported growth and gross margins quarter-to-quarter. Natural hedging via matched expenses and selective forward hedges has been used to stabilize results. Pricing corridors should be set to reflect realistic currency bands and pass-through limits.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher global policy rates — US federal funds at 5.25–5.50% and Bank of Canada at ~5.00% in mid‑2025 — lift the cost of debt and compress specialty‑pharma valuations, making refinancing windows and covenant headroom critical for Medexus’s growth and in‑licensing deals. Predictable cash flows strengthen negotiating leverage, while tight working capital and faster inventory turns preserve liquidity for strategic investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer mix and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePayer shifts toward public programs and managed care raise rebate and discount pressure (Medicaid statutory minimum rebate 23.1%), squeezing Medexus’s net realization as gross-to-net erosion for specialty drugs runs roughly 20–40%. Buy-and-bill and ASP-based rules plus specialty pharmacy fees further compress margins; real-world evidence enables value-based pricing conversations with payers (100+ US value-based contracts by 2023–24).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedicaid rebate 23.1%\u003c\/li\u003e\n\u003cli\u003eSpecialty drugs ≈50–55% of US drug spend (2023–24)\u003c\/li\u003e\n\u003cli\u003eGross-to-net erosion 20–40%\u003c\/li\u003e\n\u003cli\u003e100+ value-based contracts (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and COGS inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAPI and excipient costs, freight and cold-chain logistics remain elevated and volatile, increasing COGS pressure for Medexus and amplifying margin sensitivity; single-source components raise risk premiums and probability of stockouts for critical allergy and chronic-therapy inputs. Long-term supply agreements and dual sourcing can stabilize input pricing and protect margins, while SIOP planning aligns inventory to seasonal peak demand in allergy and chronic segments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPI\/excipient volatility increases COGS risk\u003c\/li\u003e\n\u003cli\u003eFreight and cold-chain premiums add margin pressure\u003c\/li\u003e\n\u003cli\u003eSingle-source parts = higher stockout risk\u003c\/li\u003e\n\u003cli\u003eLong-term contracts and dual sourcing mitigate cost shocks\u003c\/li\u003e\n\u003cli\u003eSIOP aligns inventory to seasonal allergy\/chronic demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNorth American footprint makes Medicare, pCPA, regulatory timing and supply risk margin drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty medicines (~49.6% global spend 2023) show demand resilience but face payer austerity; US employer coverage ~49% (2023) shifts uptake risk. USD\/CAD ~1.35–1.37 (2024) and Fed funds 5.25–5.50% (mid‑2025) raise FX and funding costs; gross‑to‑net erosion 20–40% and Medicaid rebate 23.1% squeeze net margins; API\/logistics volatility lifts COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share\u003c\/td\u003e\n\u003ctd\u003e49.6% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS employer coverage\u003c\/td\u003e\n\u003ctd\u003e49% (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSD\/CAD\u003c\/td\u003e\n\u003ctd\u003e1.35–1.37 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50% (mid‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross‑to‑net\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid rebate\u003c\/td\u003e\n\u003ctd\u003e23.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMedexus Pharma PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview of the Medexus Pharma PESTLE Analysis is the exact document you’ll receive after purchase—fully formatted and ready to use. The content, layout and structure shown here match the downloadable file with no placeholders or surprises. Purchase delivers this finished, professional analysis instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675474116985,"sku":"medexus-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/medexus-pestle-analysis.png?v=1755809175","url":"https:\/\/portersfiveforce.com\/products\/medexus-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}